The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase III trial of capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer (CAPItello290).
 
Peter Schmid
Employment - Genentech (I); Roche (I)
Honoraria - AstraZeneca; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Celgene; Eisai; Genentech/Roche (I); Merck; Novartis; Pfizer; Puma Biotechnology
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Genentech (Inst); Novartis (Inst); Oncogenex (Inst); Roche (Inst)
 
Javier Cortes
Stock and Other Ownership Interests - MedSIR
Honoraria - Celgene; Daiichi Sankyo; Eisai; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Samsung
Consulting or Advisory Role - AstraZeneca; Athenex; Bioasis; Biothera; Celgene; Cellestia Biotech; Clovis Oncology; Daiichi Sankyo; ERYTECH Pharma; GlaxoSmithKline; Leuko; Lilly; Merck Sharp & Dohme; Merus; Polyphor; Roche; Seagen; SERVIER
Research Funding - ARIAD (Inst); AstraZeneca (Inst); Baxalta (Inst); Bayer (Inst); Eisai (Inst); Guardant Health (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Piqur (Inst); Puma Biotechnology (Inst); Queen Mary university of London (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Daiichi Sankyo; Eisai; Novartis; Pfizer; Roche
 
Mark E. Robson
Honoraria - AstraZeneca
Consulting or Advisory Role - Change HealthCare
Research Funding - Abbvie (Inst); AstraZeneca (Inst); InVitae (Inst); Medivation (Inst); Myriad Genetics (Inst); Pfizer (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Pfizer
Other Relationship - Clinical Care Options; Physicans' Education Resource; Research to Practice
(OPTIONAL) Uncompensated Relationships - Daiichi Sankyo; Merck; Pfizer
 
Hiroji Iwata
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Lilly Japan; Novartis; Pfizer
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly Japan; Novartis; Pfizer
Research Funding - AstraZeneca (Inst); Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Pfizer (Inst)
 
Roberto Hegg
Speakers' Bureau - Lilly; Novartis; Roche
Research Funding - AstraZeneca; Bristol-Myers Squibb; Lilly; MSD; Novartis; Roche
Travel, Accommodations, Expenses - Pierre Fabre; Roche
 
Marina Nechaeva
No Relationships to Disclose
 
Binghe Xu
Speakers' Bureau - AstraZeneca; Eisai; Pfizer; Roche
Research Funding - Jiangsu Hengrui Medicine (Inst)
 
Sunil Verma
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Vincent Haddad
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Esteban Rodrigo Imedio
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Gaia Schiavon
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Andrew Foxley
Employment - AstraZeneca
Leadership - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
Consulting or Advisory Role - Athenex
Travel, Accommodations, Expenses - AstraZeneca
 
Yeon Hee Park
Honoraria - AstraZeneca; Eisai; Merck; Novartis; Pfizer; Roche; Samsung Bioepis
Consulting or Advisory Role - AstraZeneca; Eisai; Hanmi; Lilly; Merck; Novartis; Pfizer; Roche
Speakers' Bureau - Merck; Pfizer; Roche
Research Funding - AstraZeneca; Merck; Novartis; Pfizer; Roche
Patents, Royalties, Other Intellectual Property - Hanmi
Travel, Accommodations, Expenses - Eisai; Merck; Pfizer